Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - Galata study
- Ayvaz, Göksun
- Keskin, Lezzan
- Akın, Fulya
- Dökmetaş, Hatice Sebile
- Taşan, Ertuǧrul
- Baloğlu Ar, İdilhan
- Uren, Emel
DOIAbstract
WOS: 000351925900004PubMed ID: 25697921Objective: To evaluate tolerability/safety and the efficacy of the combination of vildagliptin plus metformin in a real-life population of patients with type 2 diabetes mellitus (T2DM). Research design and methods: This multicenter, single-arm, 6 month, observational, prospective cohort study was conducted at 39 centers across Turkey. T2DM patients on vildagliptin and metformin for = 10%), age (65 years) and body mass index (= 30 kg/m(2)) (p<0.001 each). In total, 136 adverse events (AEs) were observed in 71 (10.7%) patients; 10 (1.5%) patients experienced hypoglycemia and gastrointestinal AEs were most commonly reported (n = 29, 4.4%). Conclusions: In a 'real-life' setting, the vildagliptin and metfor...
Add to ORKG